Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

InspireMD (NSPR) EBIT (2016 - 2025)

InspireMD's EBIT history spans 16 years, with the latest figure at $27.3 million for Q4 2025.

  • For Q4 2025, EBIT rose 56.64% year-over-year to $27.3 million; the TTM value through Dec 2025 reached -$10.2 million, down 52.51%, while the annual FY2025 figure was -$10.2 million, 52.51% down from the prior year.
  • EBIT reached $27.3 million in Q4 2025 per NSPR's latest filing, up from -$13.1 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $27.3 million in Q4 2025 to a low of -$13.1 million in Q3 2025.
  • Average EBIT over 5 years is -$3.6 million, with a median of -$4.8 million recorded in 2022.
  • Peak YoY movement for EBIT: tumbled 83.64% in 2021, then soared 400.05% in 2024.
  • A 5-year view of EBIT shows it stood at -$3.9 million in 2021, then decreased by 25.57% to -$4.9 million in 2022, then decreased by 17.67% to -$5.8 million in 2023, then skyrocketed by 400.05% to $17.4 million in 2024, then skyrocketed by 56.64% to $27.3 million in 2025.
  • Per Business Quant, the three most recent readings for NSPR's EBIT are $27.3 million (Q4 2025), -$13.1 million (Q3 2025), and -$13.0 million (Q2 2025).